'Safety endpoints' diaporamas de présentation

Safety endpoints - PowerPoint PPT Presentation

Atrial Fibrillation Guideline Update

Atrial Fibrillation Guideline Update

DRO-062811000 Approved: 6-30-11. Atrial Fibrillation Guideline Update. Focus on Pharmacotherapy and New Paradigms of Therapy Dennis J. Jacobsen, Ph.D. FAHA, FACSM Medical Affairs, sanofi. Background/Disclosures. UNK (Chemistry/Biology) University of MN (MS, Physiology)

★ ★ ★ ★ ★

1.18k views • 50 slides
Outcome Measurement for Assisted Reproductive Technology

Outcome Measurement for Assisted Reproductive Technology

Outcome Measurement for Assisted Reproductive Technology. DAVID L. KEEFE, M.D. Tufts New England Medical Center, Boston, Massachusetts Laboratory for Reproductive Medicine, Marine Biological Laboratory, Woods Hole, MA Brown University, and Women & Infants Hospital, Providence, RI .

★ ★ ★ ★ ★

532 views • 33 slides
TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel

TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel

TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel. TRITON-TIMI 38 AHA 2007 Orlando, Florida.

★ ★ ★ ★ ★

483 views • 24 slides
Big Issues

Big Issues

Considerations for the choice and interpretation of endpoints in international trials of antiretroviral therapies Victor De Gruttola. Big Issues. When do results from a study in one region apply to another region?

★ ★ ★ ★ ★

313 views • 23 slides
Clinical Research and Development in the Pharmaceutical and Biotechnology Industry

Clinical Research and Development in the Pharmaceutical and Biotechnology Industry

Clinical Research and Development in the Pharmaceutical and Biotechnology Industry. Robert Anderson, MHA, CCRA, CCRCP Director, Clinical Trials Administration www.cratraininginstitute.com Houston Texas. Objectives. To understand the drug development process

★ ★ ★ ★ ★

737 views • 17 slides
Montalescot G, et al. Lancet 2009;373:723-31

Montalescot G, et al. Lancet 2009;373:723-31

Montalescot G, et al. Lancet 2009;373:723-31. Trial profile. Montalescot G, et al. Lancet 2009;373:723-31. Baseline characteristics of STEMI cohort, by drug allocation and type of PCI. Montalescot G, et al. Lancet 2009;373:723-31. Major efficacy and safety endpoints at 30 days.

★ ★ ★ ★ ★

219 views • 6 slides
ABPI NaBDEN: Areas of interest for ITTP studentships

ABPI NaBDEN: Areas of interest for ITTP studentships

Cellular and molecular mechanisms that underpin organ toxicities, with special focus on CNS, the immune system, kidney, testicular, pulmonary, liver and cardiovascular toxicity

★ ★ ★ ★ ★

247 views • 1 slides

View Safety endpoints PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Safety endpoints PowerPoint presentations. You can view or download Safety endpoints presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.